{
    "clinical_study": {
        "@rank": "164856", 
        "arm_group": [
            {
                "arm_group_label": "mFFX", 
                "arm_group_type": "Active Comparator", 
                "description": "mFOLFIRINOX"
            }, 
            {
                "arm_group_label": "mFFX+SBRT", 
                "arm_group_type": "Experimental", 
                "description": "mFOLFIRINOX + SBRT"
            }
        ], 
        "brief_summary": {
            "textblock": "A Pancreatic Cancer Radiotherapy Study Group (PanCRS) Trial\n\n      Primary Objective:\n\n      To determine progression free survival for mFFX +/- SBRT.\n\n      Secondary Objectives:\n\n        -  To determine metastasis free survival following mFFX chemotherapy alone or with SBRT.\n\n        -  To determine the overall survival in pancreatic cancer patients treated with\n           chemotherapy +/- SBRT.\n\n        -  To determine local progression-free survival in pancreatic cancer patients after\n           chemotherapy +/- SBRT.\n\n        -  To evaluate acute (within 3 months of treatment) grade 2 or greater gastritis, fistula,\n           enteritis, or ulcer and any other grade 3-4 gastrointestinal toxicity within 3 months\n           of treatment.\n\n        -  To evaluate the utility of FDG-PET for treatment planning and estimation of progression\n           free survival.\n\n        -  To identify new biomarkers in pancreatic cancer.\n\n        -  To evaluate the quality of life of patients before and after either chemotherapy or\n           chemotherapy and SBRT."
        }, 
        "brief_title": "Phase III FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer", 
        "condition": "Pancreatic Cancer", 
        "condition_browse": {
            "mesh_term": "Pancreatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "A Pancreatic Cancer Radiotherapy Study Group (PanCRS) Trial\n\n      Primary Objective:\n\n      To determine progression free survival for mFFX +/- SBRT.\n\n      Secondary Objectives:\n\n        -  To determine metastasis free survival following mFFX chemotherapy alone or with SBRT.\n\n        -  To determine the overall survival in pancreatic cancer patients treated with\n           chemotherapy +/- SBRT.\n\n        -  To determine local progression-free survival in pancreatic cancer patients after\n           chemotherapy +/- SBRT.\n\n        -  To evaluate acute (within 3 months of treatment) grade 2 or greater gastritis, fistula,\n           enteritis, or ulcer and any other grade 3-4 gastrointestinal toxicity within 3 months\n           of treatment.\n\n        -  To evaluate the utility of FDG-PET for treatment planning and estimation of progression\n           free survival.\n\n        -  To identify new biomarkers in pancreatic cancer.\n\n        -  To evaluate the quality of life of patients before and after either chemotherapy or\n           chemotherapy and SBRT."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed adenocarcinoma of the pancreas.\n\n          -  Induction mFolfirinox no more than 2 cycles.\n\n          -  Stable or better disease on re-staging scans following induction mFolfirinox.\n             Determined unresectable by a pancreatic cancer surgeon or a multi-disciplinary or\n             gastrointestinal oncology Tumor Board.\n\n          -  SBRT treatment plan must satisfy all normal tissue constraints.  Minor protocol\n             deviations will be considered on an individual basis and must be approved by\n             Coordinating Center Principal Investigator or Co-Investigator.\n\n          -  Age >18 years.\n\n          -  Karnofsky >70% (see Appendix II).\n\n          -  Acceptable organ and marrow function (as defined in Section 3.1).\n\n          -  Women who are not post-menopausal (defined in Appendix III) should have a negative\n             urine or serum pregnancy test.\n\n          -  Women and men of childbearing potential must agree to use adequate contraception for\n             the duration of study participation.\n\n        Exclusion Criteria:\n\n          -  No metastatic disease.\n\n          -  No prior upper abdominal or liver radiation therapy.\n\n          -  Chemotherapy other than 2 cycles mFolfirinox.\n\n          -  No uncontrolled illness or active infection requiring systemic antibiotic treatment.\n\n        No concurrent malignancies other than non-melanoma skin cancer, non-invasive bladder\n        cancer and carcinoma in situ of the cervix; and no other cancers within 5 years."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "172", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01926197", 
            "org_study_id": "PANC0015", 
            "secondary_id": "27492"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "mFFX", 
                    "mFFX+SBRT"
                ], 
                "intervention_name": "Oxaliplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "mFFX+SBRT", 
                "intervention_name": "SBRT", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": [
                    "mFFX", 
                    "mFFX+SBRT"
                ], 
                "intervention_name": "Irinotecan", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "mFFX", 
                    "mFFX+SBRT"
                ], 
                "intervention_name": "Leucovorin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "mFFX", 
                    "mFFX+SBRT"
                ], 
                "intervention_name": "5FU", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Leucovorin", 
                "Levoleucovorin", 
                "Oxaliplatin", 
                "Irinotecan"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 28, 2014", 
        "location": {
            "contact": {
                "email": "lcolumbo@stanford.edu", 
                "last_name": "Laurie Ann Columbo", 
                "phone": "650-736-0792"
            }, 
            "facility": {
                "address": {
                    "city": "Stanford", 
                    "country": "United States", 
                    "state": "California"
                }, 
                "name": "Stanford University Cancer Institute"
            }, 
            "investigator": {
                "last_name": "Albert Koong", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Phase III Study Evaluating Modified FOLFIRINOX (mFFX) With or Without Stereotactic Body Radiotherapy (SBRT) in the Treatment of Locally Advanced Pancreatic Cancer", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "difference in progression-free survival between mFOLFIRINOX alone vs. mFOLFIRINOX and SBRT", 
            "safety_issue": "No", 
            "time_frame": "one year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01926197"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Stanford University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Stanford University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Intervention Model: Parallel Assignment, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}